GLUT‐1 expression and response to chemoradiotherapy in rectal cancer

Preoperative chemoradiotherapy is used in locally advanced rectal cancer to reduce local recurrence and improve operability, however a proportion of tumors do not undergo significant regression. Identification of predictive markers of response to chemoradiotherapy would improve patient selection and...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2009-12, Vol.125 (12), p.2778-2782
Main Authors: Brophy, Sarah, Sheehan, Katherine M., McNamara, Deborah A., Deasy, Joseph, Bouchier‐Hayes, David J., Kay, Elaine W.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Biomarkers, Tumor - metabolism
chemoradiotherapy
Combined Modality Therapy
Female
Gastroenterology. Liver. Pancreas. Abdomen
Glucose Transporter Type 1 - metabolism
GLUT‐1
Humans
hypoxia
Immunoenzyme Techniques
Male
Medical sciences
Middle Aged
p53
Preoperative Care
Prognosis
rectal cancer
Rectal Neoplasms - drug therapy
Rectal Neoplasms - metabolism
Rectal Neoplasms - radiotherapy
Rectal Neoplasms - therapy
Retrospective Studies
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Treatment Outcome
Tumor Suppressor Protein p53 - metabolism
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Preoperative chemoradiotherapy is used in locally advanced rectal cancer to reduce local recurrence and improve operability, however a proportion of tumors do not undergo significant regression. Identification of predictive markers of response to chemoradiotherapy would improve patient selection and may allow response modification by targeting of specific pathways. The aim of this study was to determine whether expression of glucose transporter‐1 (GLUT‐1) and p53 in pretreatment rectal cancer biopsies was predictive of tumor response to chemoradiotherapy. Immunohistochemical staining for GLUT‐1 and p53 was performed on 69 pretreatment biopsies and compared to tumor response in the resected specimen as determined by the tumor regression grade (TRG) scoring system. GLUT‐1 expression was significantly associated with reduced response to chemoradiotherapy and increasing GLUT expression correlated with poorer response (p = 0.02). GLUT‐1 negative tumors had a 70% probability of good response (TRG3/4) compared to a 31% probability of good response in GLUT‐1 positive tumors. GLUT‐1 may be a useful predictive marker of response to chemoradiotherapy in rectal cancer. © 2009 UICC
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.24693